


## PHARMACEUTICAL 2022

## Phathom Pharmaceuticals Inc. Rank 374 of 475





## PHARMACEUTICAL 2022

## Phathom Pharmaceuticals Inc. Rank 374 of 475

The relative strengths and weaknesses of Phathom Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Phathom Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Phathom Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is -329%, being 53% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	186,526
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,921
Liabilities, Non-Current	98,354
Other Assets	2,255
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-8,803
Property and Equipment	650
Research and Development	72,338
Revenues	0
Selling, General and Administrative Expense	62,742

Output Variable	Value in 1000 USD
Assets	189,431
Liabilities	117,275
Expenses	135,080
Stockholders Equity	72,156
Net Income	-143,883
Comprehensive Net Income	-143,883
Economic Capital Ratio	-329%